Weiss Ratings Reaffirms “Sell (E+)” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Weiss Ratings reissued their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report sent to investors on Friday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Tuesday, February 25th.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.56 on Friday. The business has a 50-day moving average of $3.74 and a 200 day moving average of $5.23. 60 Degrees Pharmaceuticals has a 12 month low of $1.54 and a 12 month high of $35.99. The stock has a market capitalization of $2.30 million, a price-to-earnings ratio of -0.15 and a beta of 4.52.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.